The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.
The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.
The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.
The investigators used gene expression, chromatin interaction, and functional annotations to prioritize 191 genes as targets of potentially causal variants.
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
Veracyte will provide Acerta Pharma, a division of AstraZeneca, with genomic information to support its development of oncology therapeutics.
Palmetto has expanded coverage of the ClonoSeq assay to include monitoring MRD testing for patients with chronic lymphocytic leukemia (CLL.)
More groups are now using CTC capture methods alongside circulating tumor DNA tools to distinguish themselves from the crowded ctDNA detection space.
As part of the collaboration, UNC will use the firm's BarreGen assay to target molecular changes to predict resistance or relapse following ablation.
A federal court said Guardant CEO Helmy Eltoukhy deleted emails pertaining to two similar cases, but it remains unclear whether he did so intentionally.
The company will use the proceeds to strengthen its balance sheet and support the commercial launch of new products and development activities over the coming year.
The LCD for the RNA gene expression test will take effect on Feb. 10, 2020, the Medicare contractor said.
Despite the availability of more precision therapies and complex biomarker tests, systemic gaps and lack of physician education continued to hinder access.
The fledgling company, started as a promise to the founder's dying sister, is trying to succeed in a consumer niche where so many others have failed.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.
A Sun-Yat Sen University Cancer Center-led team found circulating tumor DNA methylation patterns could detect colorectal cancer among asymptomatic individuals.
Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database.
The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.
An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.
DNA testing confirms captured Chicago coyote same as the one that bit a boy near a nature museum, the Chicago Tribune reports.
An analysis of Tibetan ice cores uncovers more than two dozen previously unknown virus groups, LiveScience reports.
In Nature this week: genomic analysis of four children buried in Cameroon approximately 3,000 and 8,000 years ago, and more.